Piramal Pharma to acquire additional 41 percent stake in Yapan Bio, making it subsidiary

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹214.29

prior close

₹214.79

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%-0.3% vs market

Pharmaceuticals peers, median of 164sector+0.1%-0.2% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Smallcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+1.0

15m

+0.8

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1+0.2-0.3+0.1-0.2

Next day

-2.1-0.1-2.0-0.4-1.7

-0.9+0.1-1.0+0.1-1.0

-2.8-0.4-2.5-0.4-2.4

-4.6-0.2-4.4-0.9-3.7

-1.8+0.0-1.8-0.5-1.4

+1.1-0.0+1.2-1.2+2.3

15d

-0.6+0.1-0.7-0.8+0.3

-1.3-0.0-1.3+1.1-2.4

-7.8-3.1-4.7-3.1-4.8

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma's Admin Committee approved exercising a call option to acquire an additional 41 percent equity stake in Yapan Bio Private Limited, currently an associate company. Post-acquisition, Piramal's holding will rise from 33.33 percent to about 74 percent, making Yapan a subsidiary. Yapan is a CDMO specializing in vaccine and biologics process development and Phase I/II GMP manufacturing. Final terms including consideration and effective date are yet to be finalized.

Likely market impact

Strengthens strategic control over Yapan's vaccine and biologics CDMO business, enabling fuller consolidation of revenues and earnings as a subsidiary.